Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites by Fernandez, Pablo et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Malaria Journal
Open Access Research
Var2CSA DBL6-epsilon domain expressed in HEK293 induces 
limited cross-reactive and blocking antibodies to CSA binding 
parasites
Pablo Fernandez1, Nicola KViebig1, Sébastien Dechavanne2, 
Catherine Lépolard2, Jürg Gysin2,3, Artur Scherf1 and Benoit Gamain*1
Address: 1Institut Pasteur, Unité de Biologie des Interactions Hôte-Parasite, CNRS URA2581, Batiment Nicolle, 25, rue du Docteur Roux, F-75724 
Paris Cedex 15, France, 2Unité de Parasitologie Expérimentale, Université de la Méditerranée, Marseille, France and 3Host Pathogen Interactions 
Unit, Institut Pasteur, Abymes, France
Email: Pablo Fernandez - fpablo@pasteur.fr; Nicola KViebig - nicki.viebig@gmx.de; Sébastien Dechavanne - seb.dechavanne@laposte.net; 
Catherine Lépolard - catherine.lepolard@medecine.univ-mrs.fr; Jürg Gysin - jgysin@pasteur-guadeloupe.fr; Artur Scherf - ascherf@pasteur.fr; 
Benoit Gamain* - bgamain@pasteur.fr
* Corresponding author    
Abstract
Background:  Pregnancy-associated malaria (PAM) is a serious consequence of Plasmodium falciparum-infected
erythrocytes sequestration in the placenta through the adhesion to the placental receptor chondroitin sulfate A (CSA).
Although women become resistant to PAM as they acquire transcending inhibitory immunity against CSA-binding
parasites, hundreds of thousands of lives could be saved if a prophylactic vaccine targeting the surface proteins of
placental parasites could be designed. Recent works point to the variant protein var2CSA as the key target for the
development of a pregnancy-associated malaria vaccine. However, designing such a prophylactic vaccine has been
hindered by the difficulty in identifying regions of var2CSA that could elicit broadly neutralizing and adhesion-blocking
antibodies.
Methods: Var2CSA is a very large protein with an estimated molecular weight of 350 kDa, and can be divided into six
cysteine rich Duffy binding-like domains (DBL). The human embryonic kidney 293 cell line (HEK293) was used to
produce secreted soluble recombinant forms of var2CSA DBL domains. The Escherichia coli expression system was also
assessed for the domains not expressed or expressed in low amount in the HEK293 system. To investigate whether
var2CSA binding DBL domains can induce biologically active antibodies recognizing the native var2CSA and blocking the
interaction, mice were immunized with the refolded DBL3-X or the HEK293 secreted DBL6-ε domains.
Results: Using the HEK293 expression system, DBL1-X, DBL4-ε and DBL6-ε were produced at relatively high levels in
the culture supernatant, while DBL3-X and DBL5-ε were produced at much lower levels. DBL2-X and DBL3-X domains
were obtained after refolding of the inclusion bodies produced in E. coli. Importantly, mice antisera raised against the
recombinant DBL6-ε domain, specifically reacted against the surface of CSA-binding parasites and revealed adhesion
blocking activity.
Conclusion: This is the first report showing inhibitory binding antibodies obtained through a var2CSA recombinant DBL
domain immunization protocol. These results support the current strategies using var2CSA as immunogen in the aim of
blocking placental sequestration of malaria parasites. This work is a step towards the development of a var2CSA based
vaccine that will prevent pregnancy-associated malaria and improve pregnancy outcomes.
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Background
Pregnancy-associated malaria (PAM) has serious adverse
outcomes such as low birth weight neonates, increased
perinatal and maternal mortality, anaemia and increased
risk of hypertension in first-time pregnant mothers [1,2].
PAM is coupled with massive accumulation of parasitized
erythrocytes (PEs) and monocytes in the placental inter-
villous blood spaces [3,4]. The basis for this accumulation
in the placenta results from the capacity of placental PEs
to bind to chondroitin sulfate A (CSA) but not to CD36, a
common receptor for PEs sequestration in the microvas-
culature [5]. In endemic areas, women acquire antibodies
against placental parasites over successive pregnancies, as
they become resistant to PAM [6]. Women who have
acquired antibodies against placental PEs have higher
haemoglobin levels, deliver heavier babies and are much
less susceptible to PAM than primigravid and HIV-
infected women lacking these antibodies [7-9]. Further-
more, naturally acquired antibodies from multigravid
women react against placental PEs or CSA-binding para-
sites collected around the world, indicating that target
epitopes are globally conserved [6,10-12].
Recent evidences suggest that var2CSA, a member of the
Plasmodium falciparum Erythrocyte Membrane Protein 1
(PfEMP1) family, may have an important role in PAM dis-
ease and immunity [13]. PfEMP1 proteins are clonally
variant parasite adhesion ligands expressed on the surface
of infected erythrocytes [14,15]. Var2CSA is a very large
protein with an estimated molecular weight of 350 kDa,
and can be divided into six Duffy binding-like domains
(DBL1-6). Among them DBL2-X, DBL3-X and DBL6-ε
specifically bind to CSA [16]. Var2csa gene orthologs are
present in all parasite isolates [17] and are transcription-
ally upregulated in both placental isolates and laboratory
parasites selected to bind CSA [18-20]. Importantly,
var2csa knock-out parasites revealed that no other parasite
ligand can promote massive adhesion in the placenta [21-
23]. Furthermore, the var2CSA protein is the target of nat-
urally acquired maternal antibodies and the presence of
var2CSA specific IgG has been correlated with higher birth
weight babies [24-26].
All these data point to var2CSA as the key target for the
development of a PAM vaccine, but a number of obstacles
need to be overcome, such as the identification of regions
in the large polymorphic molecule (350 kDa) able to
induce broadly transcendent neutralizing antibodies that
would de-sequester and/or mediate parasite phagocytosis.
Given the var2CSA protein size, strategies to express the
entire protein are not envisaged, but expression of cor-
rectly folded and biologically active cysteine-rich DBL
domains is the most promising strategy.
In this study, an expression system was developed to pro-
duce recombinant DBL domains in the culture superna-
tant of transiently transfected Human Embryonic Kidney
293 cell line (HEK293) grown in serum-free medium in
suspension. Using the HEK293 cell expression system,
five DBL domains out of six were successfully secreted in
the growth medium. As DBL2-X and DBL3-X were not
found or found in low amount in the HEK293 growth
medium, their expression in Escherichia coli was evaluated.
Previously described CSA binding domains DBL3-X and
DBL6-ε were then chosen to raise antisera in mice in order
to evaluate their capacity to induce antibodies recognizing
the PEs surface of different CSA-binding strains and for
their capacity to inhibit FCR3-CSA PEs binding to Sc1D
cells in static adhesion experiments.
Methods
HEK293 DBL expression and purification
Var2csa  synthetic genes were designed with optimized
codons for human expression. Synthetic genes encoding
FCR3 var2CSA DBL domains (accession AY372123);
DBL1-X (residues 58–383), DBL2-X (residues 530–863),
DBL3-X (residues 1221–1548), DBL4-ε (residues 1594–
1888), DBL5-ε (residues 2003–2270) and DBL6-ε (resi-
dues 2322–2590) were cloned into the pTT3 vector
between the EcoRI and BamHI restriction sites. Synthetic
genes contained an N-terminal murine Ig κ-chain leader
sequence to allow secretion of the proteins [27] and a
His6-tag on the C-terminus. Potential N-glycosylation
sites were removed from synthetic genes by converting
asparagine to glutamine or by replacing asparagine with
an amino acid from another var2csa allele (Table 1).
FreeStyle 293-F cells (Invitrogen) were grown in Freestyle
293 serum free expression medium and transfected with
the pTT3 vector containing the synthetic genes following
Invitrogen's recommendations. 72 hours post-transfec-
tion, cells were centrifuged and the culture medium was
harvested. After filtration on a 0.22 μm filter, supernatants
were concentrated five times using a 10 kDa cut-off Viva-
flow 200 System (Vivasciences). Samples were then diafil-
trated against PBS pH 7.2 (GIBCO) supplemented to 500
mM NaCl final concentration and charged on a HisTrap
FF Ni-affinity column (GE Healthcare) previously equili-
brated with the same buffer, and connected to an FPLC
Akta System (Amersham Pharmacia Biotech). After wash-
ing, proteins were eluted with an imidazole gradient (0 to
0.5 M). Aliquots containing purified DBL domains were
pooled and dialyzed against 0.9% NaCl. Purified proteins
were subsequently concentrated using Macro- and Micro-
sep concentrators (Pall/Gellman). Protein concentrations
were determined using the Bio-Rad protein assay. Purity
of the samples was checked by SDS-PAGE and Western
blot.Malaria Journal 2008, 7:170 http://www.malariajournal.com/content/7/1/170
Page 3 of 11
(page number not for citation purposes)
Prokaryotic expression, refolding and purification
Synthetic genes encoding for var2CSA DBL2-X and DBL3-
X were designed with optimized codons for E. coli expres-
sion. Synthetic genes encoding FCR3 var2CSA (accession
AY372123) DBL2-X (residues 530–863) and DBL3-X (res-
idues 1221–1548) domains fused to a His6-tag on the C-
terminus were cloned into the pET24a expression vector
between the NdeI and EcoRI restriction sites. Transformed
E. coli BL21 (DE3) cells were grown at 37°C in LB
medium with 30 μg/ml of kanamycin to an absorbance of
0.5 at 600 nm, and were then induced with 1.0 mM iso-
propyl-β-D-thiogalactopyranoside (IPTG) for 3 h at 37°C
under good aeration. Cells were harvested by centrifuga-
tion at 6,000 g. The pellets from 800 ml of culture were
resuspended in 30 ml of 50 mM Tris.HCl, pH 8.5, con-
taining 150 mM NaCl, in the presence of protease inhibi-
tors. The cells were disrupted by sonication on ice and the
suspensions were centrifuged for 20 min at 5,000 g. Pel-
lets were resuspended and washed twice with 30 ml of 50
mM Tris.HCl, pH 8.5, containing 150 mM NaCl, in the
presence of protease inhibitors, and finally centrifuged for
20 min at 10,000 g. The pellets containing DBL2-X or
DBL3-X inclusion bodies were then denatured overnight
at 25°C under agitation in 50 mM Tris.HCl pH 8.5 buffer,
containing 150 mM NaCl, 8 M Urea and 5 mM Dithioth-
reitol (DTT). The suspensions were centrifuged for 30 min
at 15,000 g and the pellet was discarded. Refolding was
assayed with the AthenaES™ kit (Athena Environmental
Sciences, Inc.) according to the manufacturer's instruc-
tions. Once the best condition was established, denatured
proteins were immobilized on a HisTrap FF Ni-affinity
column previously equilibrated with the same buffer, and
connected to an FPLC Akta System. The proteins were
refolded on the column by adding quickly the refolding
buffer (50 mM Tris.HCl pH 8.5, 20 mM NaCl, 0.4 mM
KCl, 0.5% Triton-X-100 and 0.5 mM DTT). After extensive
washing with the refolding buffer without Triton-X-100,
the protein was eluted with an imidazole gradient (0 to
0.5 M) and aliquots containing purified DBL domains
were pooled. After dialysis against 0.9% NaCl and concen-
tration by means of Macro- and Micro-sep concentrators,
a further stage of gel filtration (Superdex 75, Amersham
Pharmacia Biotech) was required to separate the mono-
meric proteins from the aggregated material and other
impurities. Purified DBLs were subsequently concentrated
by means of Macro- and Micro-sep concentrators. Protein
concentration was determined using the Bio-Rad protein
assay. Purity of the samples was checked by SDS-PAGE
and Western blot.
Free thiol content was estimated using the Ellman's Rea-
gent (Pierce) by comparison to a cysteine standard curve
composed of known concentrations of Cysteine Hydro-
chloride Monohydrate following Pierce's recommenda-
tions.
Parasite and cell culture
The P. falciparum FCR3, HB3 and 7G8 strains were main-
tained in culture according to standard conditions in O+
human erythrocytes in RPMI 1640 containing L-
glutamine (Invitrogen) supplemented with 5% Albumax
I, 1× hypoxanthine and 20 μg/ml gentamicin [28]. To
maintain knob-positive parasites, cultures were routinely
selected by gelatin flotation using Plasmion (Fresenius
Kabi) [29]. Parasites were tested Mycoplasma negative by
PCR. Laboratory isolates, FCR3, 7G8 and HB3 were ini-
tially selected on bovine CSA or on the human choriocar-
cinoma placenta BeWo cell line and subsequently
maintained by panning to the BeWo cell line as previously
described [30]. CD36 or CSA binding phenotypes of PEs
were verified on receptors immobilized on plastic Petri
dishes as previously described [30].
Balb/c immunization
Two groups of three Balb/c mice (Charles River) received
a primary subcutaneous injection of 20 μg refolded
recombinant DBL3-X or secreted DBL6-ε protein dis-
solved in 100 μl of NaCl 0.9% and emulsified at 1:1 in
100 μl of complete Freund adjuvant (Pierce). Two addi-
tional injections were performed at 4 week intervals by
using the same amount and antigen batches emulsified at
Table 1: N-Glycosylation sites mutated in HEK293 expressed 
DBL domains
Domains Boundaries N-Glycosylation sites mutated*
DBL1-x 58 – 383 5 N85I
N147Q
N356K
N362H
N380Q
DBL2-x 530 – 863 2 N692Q
N730Q
DBL3-x 1221 – 1548 3 N1222S
N1290Q
N1428K
DBL4-ε 1594 – 1888 4 N1674H
N1744Q
N1749Q
N1844Q
DBL5-ε 2003 – 2270 3 N2134Q
N2210Q
N2223Q
DBL6-ε 2322 – 2590 2 N2442Q
N2537Q
*Asparagine residues were changed to glutamine or, in some 
instances, to amino acids found in other var2csa alleles at this location.Malaria Journal 2008, 7:170 http://www.malariajournal.com/content/7/1/170
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1:1 in incomplete Freund adjuvant. Mice were bled by
orbital sinus puncture one day before the primary antigen
injection and each time preceding an antigen boost, and
2, 4 and 6 weeks after the 3rd and last boost. Serum sam-
ples were collected after centrifugation of the blood, de-
complemented for 30 min at 56°C and stored at -20°C
until use.
Flow cytometry
Synchronous PEs cultures (3–12% parasitaemia) at mid/
late trophozoite stages were purified using the VarioMACS
and CS columns (Miltenyi) as previously described [31]
and resuspended to 107 PEs/ml in PBS 0.2% BSA. PEs were
added to 96-well U-bottom plates and the mouse serum
(heat inactivated and pre-adsorbed on uninfected
erythocytes from mock culture) was added into the wells
to get a 1:20 dilution of serum to cell suspension (using a
final volume of 50 to 100 μl). After incubation at room
temperature for 30 min, 100 μl of PBS containing 0.2%
BSA were added, and cells were centrifuged at 2000 rpm
for 2 min. Cells were washed twice with 160 μl of PBS/
0.2% BSA and resuspended in 50 μl PBS/0.2% BSA con-
taining the secondary antibody (anti-mouse IgG Alexa
488) diluted 1:100. After incubation on ice in the dark for
30 min, cells were centrifuged and washed as before, and
resuspended in 2–4% paraformaldehyde in PBS for fixa-
tion overnight at 4°C. Fixed cells were centrifuged at 2000
rpm for 2 min and resuspended in 100 μl PBS before
transfer to flow cytometry tubes. Analysis was carried out
on a FACScan using CellQuest software (BD Biosciences).
The flow cytometer gated the PEs' population based on
forward scatter and side scatter, and cells were plotted as a
histogram by fluorescence in channel 1 (Alexa fluor®488).
At least 10000 cells were counted for each sample. The
level of fluorescence was stated as the Geometric Mean
Fluorescence Index (MFI) of all the gated cells as deter-
mined in at least two independent experiments. Data were
then converted to normalized MFI by subtracting the pre-
immune MFI value from the immune MFI value.
Inhibition experiments
Cytoadhesion microassays were performed on confluent
Saimiri brain endothelial cell (SBEC) Sc1D cells as previ-
ously described [32]. Briefly, endothelial cells were rinsed
twice with cytoadhesion medium at pH 7.2 before the
addition to the cells of 20 μl of serum (diluted 1:5) prein-
cubated with 20 μl of PEs (at 107 cells/ml). The slides were
incubated for two hours at 37°C in a CO2 incubator. Non-
adherent PEs were removed by washing with cytoadhe-
sion medium and cytoadherent PEs were counted under a
light microscope (Nikon TMS, magnification of ×300), in
four randomly selected fields (area of 0.2827 mm2) for
each spot.
Results
Expression and Purification of recombinant DBL domains
Var2CSA is a key target for the development of a PAM vac-
cine. Due to the large protein size, the most promising
strategy is a vaccine based on var2CSA protein subunits.
Therefore, the six var2CSA DBL domains from the FCR3
strain were tested for expression as secreted His-tagged
recombinant proteins in the human embryonic cell line
HEK293. For that purpose synthetic genes were designed
with optimized codons for human expression and with an
N-terminal murine Ig κ-chain leader sequence to allow
secretion of the proteins and a His6-tag on the C-termi-
nus. As P. falciparum proteins are not N-glycosylated,
potential N-glycosylation sites were removed from syn-
thetic genes by converting asparagine to glutamine or by
replacing asparagine with an amino acid from another
var2csa allele (Table 1).
Using this expression system, DBL1-X, DBL4-ε and DBL6-
ε were produced at relatively high levels in the culture
supernatant, while DBL3-X and DBL5-ε were produced at
much lower levels (Figure 1a). No expression of DBL2-X
could be detected in the culture supernatants. However,
after cell lysis, all the recombinant proteins were found in
the insoluble fraction, indicating that some of the pro-
teins are likely to be retained in the cells due to their incor-
rect conformation.
After purification on a HisTrap FF Ni-affinity column,
highly pure recombinant (over 95%), DBL1-X, DBL4-ε
and DBL6-ε were obtained at a yield ranging from 0.6 to
5 mg/l of cell culture supernatant, while only a minimal
amount of DBL3-X was obtained (Figure 1b). Under
reducing conditions in SDS-PAGE, all four proteins
migrated at the expected molecular weight (Figure 1b).
DBL4-ε and DBL6-ε migrated as a double-band as a con-
sequence of the presence of two isoforms of the protein,
which could result from post-transductional modifica-
tions such as O-glycosylation. N-terminal sequencing and
SDS-PAGE indicated that proteins remained intact, with-
out proteolytic degradation occurring during the purifica-
tion procedures.
As the chosen strategy was to express CSA-binding
domains rather than non CSA binding domains, DBL2-X
and DBL3-X domains were tested for expression in E. coli.
For that purpose, synthetic genes encoding for var2CSA
DBL2-X and DBL3-X fused to a His6-tag on the C-termi-
nus were designed with optimized codons for E. coli
expression.
Recombinant DBL2-X and DBL3-X expressed in E. coli
accumulate in inclusion bodies as insoluble, misfolded
aggregates. Misfolded DBL domains were solubilized in 8
M urea, purified under denaturing conditions by metal-Malaria Journal 2008, 7:170 http://www.malariajournal.com/content/7/1/170
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Protein purification of FCR3 var2CSA DBL domains expressed in HEK293 Figure 1
Protein purification of FCR3 var2CSA DBL domains expressed in HEK293. a. SDS PAGE and Western blot analysis. 
NuPAGE Novex 4–12% Bis-Tris gels under reduced conditions were loaded with HEK293 extracts obtained after transfection 
with the different FCR3 var2CSA DBL domains. Gels were either stained with Coomasie blue or transferred to a PVDF mem-
brane to detect recombinant products using an anti-His Tag antibodies. Lanes 1, 2, 3, 4, 5, and 6 correspond respectively to 
DBL1-X, DBL2-X, DBL3-X, DBL4-ε, DBL5-ε, and DBL6-ε. Culture supernatant, soluble and insoluble fractions after cell lysis 
are indicated. b. Electrophoresis of purified HEK293 expressed DBL domains. NuPAGE Novex 4–12% Bis-Tris gels under 
reduced (+DTT) or non reduced (-DTT) conditions were loaded with DBL1-X, DBL3-X, DBL4-ε and DBL6-ε obtained after 
His-Tag purification and stained with Coomasie blue. Lanes 1, 3, 4, and 6 correspond respectively to DBL1-X, DBL3-X, DBL4-
ε and DBL6-ε domains. Protein yields were 0.6 mg/L for DBL1-X, 0.9 mg/l for DBL4-ε and 5 mg/l for DBL6-ε.
a.
b.
Cell lysis
Supernatant Soluble Insoluble
11 1 22 2 33 3 44 4 55 5 66 6
- -
-
- - -
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+ DTT
1346 1346
- DTTMalaria Journal 2008, 7:170 http://www.malariajournal.com/content/7/1/170
Page 6 of 11
(page number not for citation purposes)
affinity chromatography and refolding tests were carried
out by the method of rapid dilution. Using that strategy, a
buffer containing 0.5% Triton-X-100 was identified as the
best solution for refolding both insoluble recombinant
DBL domains. However, due to the incapacity to com-
pletely remove Triton X-100 through classical methods,
such as dialysis or filtration, the refolding process was
done after immobilization of the denatured proteins on a
metal-affinity column. In this procedure, DBL domains
solubilized in 8 M urea were immobilized onto the metal-
affinity column and the denaturation solution changed
rapidly for the previously identified refolding solution
containing Triton-X-100 (Figure 2a). Although due to
sudden buffer change some DBL detached from the col-
umn, an important fraction of the protein was retained on
the column. After extensive washing with the refolding
buffer without the detergent, the proteins were eluted
using an imidazole gradient (Figure 2a). After dialysis
against 0.9% NaCl, gel filtration chromatography using
Superdex 75 was performed to purify highly pure (over
95%) recombinant DBL monomers to homogeneity (Fig-
ure 2a). Using that strategy, the protein yield after refold-
ing and all purification steps was 4 mg/l of cell culture for
DBL3-X (Figure 2b) and 0.3 mg/l of cell culture for DBL2-
X (Figure 2c). Due to the low yield recovered, DBL2-X was
not further characterized. However, refolded and purified
DBL3-X was characterized using a variety of biochemical
and biophysical methods. N-terminal sequencing of
recombinant DBL3-X yields the expected sequence,
namely, MNATN. No other sequence was detected.
Refolded DBL3-X migrated slower on SDS-PAGE gels after
reduction with DTT indicating the presence of disulfide
bonds (Figure 2b). Free thiol content was estimated by the
method of Ellman to further examine the oxidation state
of refolded DBL3-X. Free thiols can be clearly detected up
to 30 μM thiol concentrations in this assay. No free thiols
are detected in refolded DBL3-X at a protein concentra-
tion of 100 μM. Given that DBL3-X contains 12 cysteines,
greater than 96% of cysteines are thus disulfide linked.
Antibodies to var2CSA DBL6-ε partially cross-react with 
different CSA binding strains
To investigate whether the recombinant var2CSA DBL
domains can induce biologically active antibodies recog-
nizing the native var2CSA, mice were immunized with the
refolded DBL3 or the HEK293 secreted DBL6-ε. Final
bleed antisera were evaluated for their capacity to recog-
nize the surface of FCR3CSA binding PEs by liquid immun-
ofluorescence and flow cytometry (Figure 3a). Two out of
the three mice immunized with DBL6-ε (DBL6-1 and
DBL6-3) had high level of antibodies recognizing the sur-
face of FCR3CSA PEs. Very low reactivity was detected for
mouse DBL6-2. However, in contrast to DBL6-ε, the
DBL3-X antisera did not react or reacted very weakly with
the surface of FCR3CSA PEs (Figure 3a).
To investigate whether mice antisera could also recognize
other var2CSA variants, flow cytometry analysis was per-
formed on two other CSA-binding parasite lines from
South America (7G8CSA) and Central America (HB3CSA)
(Figure 3b). Two out of the three mice immunized with
DBL6-ε (DBL6-2 and DBL6-3) had a significant level of
antibodies recognizing the surface of 7G8CSA PEs and a
low amount of antibodies reacting against HB3CSA (Figure
3a). Curiously all three DBL3-X immunized antisera
reacted against 7G8CSA PEs and recognized weakly the
HB3CSA strain, even if they did not recognize the surface of
the homologous strain FCR3. No significant recognition
of all the antisera was observed against the CD36 binding
parasites.
Var2CSA DBL6-ε antibodies partially inhibit CSA adhesion
In order to evaluate the inhibitory capacities of the DBL3-
X and DBL6-ε antisera, the binding of FCR3CSA PEs to the
CSA expressing endothelial cell line Sc1D was assessed in
the presence of non-immune or immune antisera at a
final 1:10 dilution. One month after the third injection
(Day 85), the three DBL6-ε immunized mice recognized
the surface of FCR3CSA binding PEs by liquid immunoflu-
orescence and inhibited PEs cytoadhesion to Sc1D cells
from 32 to 64% (Figure 4a). However, no inhibition was
observed using the DBL3-X antisera. After an additional
boost, DBL6-ε immunized mice were sacrificed and the
final bleeds were tested for inhibition. Although the final
DBL6-ε antisera bleeds recognize the surface of CSA-bind-
ing PEs (Figure 3a), almost no inhibitory activity could be
detected (Figure 4b), indicating a change in the immune
response. From these data we can conclude that the DBL6-
ε domain can induce an immune response that block PEs
adhesion, indicating that it is a critical target domain.
Discussion
Several lines of evidence point to var2CSA as the leading
vaccine candidate to prevent PAM. However, the major
limiting steps for validating this molecule as a protective
immunogen reside in its high molecular weight and the
production of sufficient functional recombinant protein.
Indeed, the var2CSA protein size (around 350 kDa) and
the hydrophobic and cysteine-rich sequence contribute to
aggregation as insoluble material upon expression in the
available prokaryotic systems. Therefore we assessed the
human embryonic kidney cell line HEK293 as a new sys-
tem for expressing var2CSA DBL domains from the FCR3
strain as secreted His-tagged recombinant proteins. Engi-
neering the expression vector with a sequence signal
allowed us to obtain high quality soluble affinity purified
material in a quick and easy way. Although the HEK293
expression system was useful for secreting in relatively
high quantity (up to 5 mg/l) three out of six different
domains in the culture supernatant, the three others were
either absent or present in very low quantities in the cul-Malaria Journal 2008, 7:170 http://www.malariajournal.com/content/7/1/170
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DBL2-X and DBL3-X expression in E. coli and purification Figure 2
DBL2-X and DBL3-X expression in E. coli and purification. a. Electrophoresis in an SDS 12% polyacrylamide gel of aliq-
uots from different steps in expression, refolding and purification of DBL3-X. Lane 1, non-induced BL21 (DE3) (containing 
pET24a-DBL3-X plasmid); lane 2, induced BL21 (DE3) containing the pET24a-DBL3-X plasmid; lane 3, inclusion bodies suspen-
sion; lane 4, inclusion bodies after washing and denaturation in Urea 8 M; lane 5, affinity column flow through; lane 6, portion of 
DBL3-X lost during refolding onto the affinity column; lane 7, affinity column elution pool; lane 8, molecular size exclusion col-
umn purified DBL3-X. b. Electrophoresis of refolded DBL3-X in a SDS 12% polyacrylamide gel before (-) and after (+) reduc-
tion with dithiothreitol (DTT). c. Electrophoresis of refolded DBL2-X in a SDS 12% polyacrylamide gel before (-) and after (+) 
reduction with dithiothreitol (DTT). Higher mobility before reduction indicates the presence of disulfide linkages.Malaria Journal 2008, 7:170 http://www.malariajournal.com/content/7/1/170
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PEs surface recognition Figure 3
PEs surface recognition. a. Anti-var2CSA DBL mouse sera were tested for surface recognition of erythrocytes infected 
with parasites of the FCR3, 7G8 and HB3 strains with CSA- and CD36 binding phenotypes, respectively. Analysis was per-
formed using flow cytometry and fluorescence microscopy. A representative example of a specific surface immunolabeling 
using the DBL6-1 antisera and the corresponding differential interferential contrast microscopy field are shown. Flow cytome-
try data shown are the normalized geometric mean fluorescence index (MFI) (± SD) obtained by subtracting the preimmune 
MFI value from the immune MFI value. b. Alignment of the DBL6-ε var2CSA sequences from the 3 parasite lines used to assess 
the antisera cross-reactivity by FACS. Conserved residues between FCR3 sequence and the other sequences are boxed with a 
yellow background.
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ture supernatant. We also showed here that antisera from
mice immunized with DBL6-ε recognized the surface of
the homologous parasite FCR3CSA and a variable degree of
cross-reactivity was observed for 7G8CSA and HB3CSA para-
sites in individual mice. As 7G8 var2CSA is closer to FCR3
var2CSA than both var2CSA variants present in HB3
(HB3.1 and HB3.2) (Figure 3b), this could explain the
higher cross-reactivity observed against the 7G8CSA PEs
surface. Considering that DBL6-ε domain is the least con-
served var2CSA DBL domain, this limited cross-reactivity
is somehow expected. It also suggests that the immunodo-
minant epitopes are in the polymorphic region, whereas
the conserved block may not be exposed in the native
var2CSA molecule (Figure 3b).
As two of the previously described CSA binding domains
present in var2CSA (DBL2-X and DBL3-X) were not
expressed or expressed in low amount in the growth
supernatant, the E. coli expression system was evaluated.
The proteins were recovered from inclusion bodies under
denaturing conditions and a column refolding based
process allowed us to obtain DBL3-X refolded material.
Surprisingly, antisera from mice immunized with DBL3-X
did not react with the surface of the homologous CSA
Inhibition of PEs adhesion Figure 4
Inhibition of PEs adhesion. Mouse antisera (1:10 dilution) were tested for inhibition of binding of PEs to Sc1D cells in static 
binding assays at D85 after immunization (a) and for final bleeds (b). The number of bound PEs in the presence of preimmune 
serum (PI) was used as a reference (100%). The numbers of bound PEs for the three anti-DBL6-ε sera were then expressed as 
a percentage relative to the PI reference value. Values represent the means of two individual experiments performed in dupli-
cates.
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binding PEs, but recognized weakly the surface of 7G8CSA
PEs. Although DBL3-X is one of the most conserved
var2CSA DBL domains, it is hard to understand why the
antisera react in a better way with a heterologous antigen
than with the homologous one. One explanation could be
due to a better accessibility to the antigen on the surface
of 7G8CSA PEs compared to FCR3CSA or HB3CSA parasites,
or that the DBL3-X domain was not correctly refolded as
it is in the context of the whole PfEMP1.
The DBL3-X and DBL6-ε immunized mice immunologi-
cal responses were also followed by testing the antisera for
their ability in blocking PEs adhesion to Sc1D cells. We
showed here that all the antisera raised against DBL6-ε
inhibited PEs adhesion with values ranging from 32% to
64% inhibition at D85 after immunization. However,
after an additional boost and even with a good surface
reactivity, the inhibitory activity was strongly reduced in
the final bleed, indicating that other epitopes are targeted
by these antisera. It is therefore conceivable that most
anti-DBL6-ε antibodies are against the surface of the CSA
binding PEs but do not inhibit adhesion. Another expla-
nation could be that some of these non-inhibitory anti-
bodies could compete with the inhibitory antibodies
preventing the latter from reaching the CSA binding
pocket. In terms of vaccine development, as it seems that
the balance between inhibitory and non-inhibitory anti-
bodies may change during the course of immunization, it
may be important to specifically target the critical regions
involved in adhesion in order to overcome this potential
problem.
Conclusion
This is the first report showing adhesion inhibitory anti-
bodies obtained through a var2CSA recombinant DBL
domain immunization protocol. These results support the
current strategies using var2CSA as immunogen in the aim
of blocking placental sequestration of malaria parasites
and set up the basis for developing a vaccine against preg-
nancy-associated malaria based on this protein.
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